Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy

Extensive research over 100 years has demonstrated that tumors can be eliminated by the autologous immune system. Without doubt, immunotherapy is now a standard treatment along with surgery, chemotherapy, and radiotherapy; however, the field of cancer immunotherapy is continuing to develop. The curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubo, Terufumi, Shinkawa, Tomoyo, Kikuchi, Yasuhiro, Murata, Kenji, Kanaseki, Takayuki, Tsukahara, Tomohide, Hirohashi, Yoshihiko, Torigoe, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289279/
https://www.ncbi.nlm.nih.gov/pubmed/34290982
http://dx.doi.org/10.3389/fonc.2021.679095
_version_ 1783724270796406784
author Kubo, Terufumi
Shinkawa, Tomoyo
Kikuchi, Yasuhiro
Murata, Kenji
Kanaseki, Takayuki
Tsukahara, Tomohide
Hirohashi, Yoshihiko
Torigoe, Toshihiko
author_facet Kubo, Terufumi
Shinkawa, Tomoyo
Kikuchi, Yasuhiro
Murata, Kenji
Kanaseki, Takayuki
Tsukahara, Tomohide
Hirohashi, Yoshihiko
Torigoe, Toshihiko
author_sort Kubo, Terufumi
collection PubMed
description Extensive research over 100 years has demonstrated that tumors can be eliminated by the autologous immune system. Without doubt, immunotherapy is now a standard treatment along with surgery, chemotherapy, and radiotherapy; however, the field of cancer immunotherapy is continuing to develop. The current challenges for the use of immunotherapy are to enhance its clinical efficacy, reduce side effects, and develop predictive biomarkers. Given that histopathological analysis provides molecular and morphological information on humans in vivo, its importance will continue to grow. This review article outlines the basic knowledge that is essential for the research and daily practice of immune checkpoint inhibitor-based cancer immunotherapy from the perspective of histopathology.
format Online
Article
Text
id pubmed-8289279
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82892792021-07-20 Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy Kubo, Terufumi Shinkawa, Tomoyo Kikuchi, Yasuhiro Murata, Kenji Kanaseki, Takayuki Tsukahara, Tomohide Hirohashi, Yoshihiko Torigoe, Toshihiko Front Oncol Oncology Extensive research over 100 years has demonstrated that tumors can be eliminated by the autologous immune system. Without doubt, immunotherapy is now a standard treatment along with surgery, chemotherapy, and radiotherapy; however, the field of cancer immunotherapy is continuing to develop. The current challenges for the use of immunotherapy are to enhance its clinical efficacy, reduce side effects, and develop predictive biomarkers. Given that histopathological analysis provides molecular and morphological information on humans in vivo, its importance will continue to grow. This review article outlines the basic knowledge that is essential for the research and daily practice of immune checkpoint inhibitor-based cancer immunotherapy from the perspective of histopathology. Frontiers Media S.A. 2021-07-05 /pmc/articles/PMC8289279/ /pubmed/34290982 http://dx.doi.org/10.3389/fonc.2021.679095 Text en Copyright © 2021 Kubo, Shinkawa, Kikuchi, Murata, Kanaseki, Tsukahara, Hirohashi and Torigoe https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Kubo, Terufumi
Shinkawa, Tomoyo
Kikuchi, Yasuhiro
Murata, Kenji
Kanaseki, Takayuki
Tsukahara, Tomohide
Hirohashi, Yoshihiko
Torigoe, Toshihiko
Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy
title Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy
title_full Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy
title_fullStr Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy
title_full_unstemmed Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy
title_short Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy
title_sort fundamental and essential knowledge for pathologists engaged in the research and practice of immune checkpoint inhibitor-based cancer immunotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289279/
https://www.ncbi.nlm.nih.gov/pubmed/34290982
http://dx.doi.org/10.3389/fonc.2021.679095
work_keys_str_mv AT kuboterufumi fundamentalandessentialknowledgeforpathologistsengagedintheresearchandpracticeofimmunecheckpointinhibitorbasedcancerimmunotherapy
AT shinkawatomoyo fundamentalandessentialknowledgeforpathologistsengagedintheresearchandpracticeofimmunecheckpointinhibitorbasedcancerimmunotherapy
AT kikuchiyasuhiro fundamentalandessentialknowledgeforpathologistsengagedintheresearchandpracticeofimmunecheckpointinhibitorbasedcancerimmunotherapy
AT muratakenji fundamentalandessentialknowledgeforpathologistsengagedintheresearchandpracticeofimmunecheckpointinhibitorbasedcancerimmunotherapy
AT kanasekitakayuki fundamentalandessentialknowledgeforpathologistsengagedintheresearchandpracticeofimmunecheckpointinhibitorbasedcancerimmunotherapy
AT tsukaharatomohide fundamentalandessentialknowledgeforpathologistsengagedintheresearchandpracticeofimmunecheckpointinhibitorbasedcancerimmunotherapy
AT hirohashiyoshihiko fundamentalandessentialknowledgeforpathologistsengagedintheresearchandpracticeofimmunecheckpointinhibitorbasedcancerimmunotherapy
AT torigoetoshihiko fundamentalandessentialknowledgeforpathologistsengagedintheresearchandpracticeofimmunecheckpointinhibitorbasedcancerimmunotherapy

Ejemplares similares